Mr. Rivard summarizes some of the key points made during the oral arguments hearing in Tafas v. Dudas, in both Managing Intellectual Property and Intellectual Property Watch. He points out that the judges did seem open to the PTO’s concerns over the growing backlog of applications, however they also appeared to be receptive to GSK’s arguments. He also addresses the unlikely possibility that USPTO’s new director withdraws the rules and abandons the appeal.
Posted: December 8, 2008
